__25J148Qli3.jpg)
我們使用 Cookie 以允許我們網站的正常工作、個性化設計內容和廣告、提供社交媒體功能並分析流量。我們還同社交媒體、廣告和分析合作夥伴分享有關您使用我們網站的信息
20
May 2026
Latest News
ScinoPharm Taiwan Focuses on Metabolic Syndrome Awareness by Promoting Balanced Plant-Based Meals for Employees
ScinoPharm Taiwan has long focused on therapeutic areas including oncology, hematology, central nervous system disorders, and metabolic diseases, while actively advancing the development of GLP-1 related APIs and Drug Products. In parallel with its commitment to pharmaceutical innovation, the company also places strong emphasis on employee wellness and disease prevention, encouraging colleagues to pay greater attention to their personal health through healthier daily habits.
Centered on the concept of “starting change from the dining table,” ScinoPharm Taiwan optimized its employee cafeteria menu by increasing the proportion of fruits and vegetables, making it easier for employees to adopt balanced dietary habits in their everyday lives. In addition, plant-based foods generally generate lower carbon emissions than animal-based products. Choosing locally sourced fruits and vegetables can further reduce transportation distances, logistics-related emissions, and food storage energy consumption, creating additional environmental benefits and contributing to broader sustainability goals.
As metabolic syndrome and chronic diseases continue to affect younger populations, enhancing health awareness and establishing proper dietary and lifestyle habits have become increasingly important for society as a whole. Through this collaboration, employees are not only encouraged to actively practice healthier behaviors themselves, but also to share concepts of healthy eating and health management with their families and social circles, gradually expanding the positive impact beyond the workplace into households and local communities.
Read More
16
Oct 2025
Latest News
ScinoPharm Taiwan Hosts Healing Art Forum in Partnership with Formosa Cancer Foundation
ScinoPharm Taiwan recently held its 16th annual ScinoPharm Art Forum, a long-standing public art and cultural lecture series dedicated to enriching lives through art and dialogue.
Read More
19
Dec 2024
Latest News
ScinoPharm Partners with Handa Pharmaceuticals to Advance 505(b)(2) Drug Development
ScinoPharm Taiwan, Ltd. today announced a strategic investment in Handa Pharmaceuticals, Inc., marking the beginning of a collaboration to share R&D resources and leverage complementary strengths in advancing 505(b)(2) new drug development. This partnership will drive efforts in research, clinical trials, regulatory approvals, and product commercialization.
Read More
20
Nov 2024
Latest News
ScinoPharm Taiwan Achieves Zero-Deficiency Record in ANVISA Inspection, Expanding Its Presence in Emerging Markets
ScinoPharm Taiwan (SPT) (stock code 1789) has not only solidified its position in the US and EU pharmaceutical markets, but is continuing to extend its reach into promising emerging markets, demonstrating its commitment to expand its global footprint.
Read More
13
Aug 2024
Latest News
ScinoPharm Taiwan H1 performance strong, expands focus on injectable and CDMO businesses
ScinoPharm Taiwan (stock code 1789) reported consolidated revenue of NT$1.646 billion for the first half of 2024, with a post-tax net profit of NT$215 million, representing a 117% increase compared to the same period last year.
Read More